Dr. Núria Lloberas Blanch, researcher in the Nephrology and Kidney Transplant group at IDIBELL and pharmacologist in the Nephrology service of the Bellvitge University Hospital, has been appointed president of the Immunosuppression Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). This is the only international organization dedicated to the study and clinical application of therapeutic drug monitoring.
Until now, Dr. Lloberas served as vice-president of the committee, and her appointment was made official during the XXIII International Congress of the IATDMCT, held last September in Singapore.
The Immunosuppression Committee, made up of 45 members from different countries and specialties, has the mission of providing evidence-based recommendations for therapeutic monitoring (TDM) of immunosuppressive agents, promoting communication between researchers and clinicians around the world, and encouraging the effective application of TDM in transplant medicine.
In addition, this committee is responsible for developing international consensus and guidelines on the use and monitoring of the main immunosuppressive drugs, reference documents in global clinical practice. It also promotes scientific and educational activities in collaboration with other international societies, with the aim of promoting good clinical practices and the personalization of immunosuppressive treatment in transplant patients.
“It is an honour to take on this responsibility in a world-renowned organisation. Our goal is to continue promoting knowledge and clinical practice in immunosuppression, favoring a more personalized and safer medicine for transplant patients,” says Dr. Lloberas.
The Bellvitge Biomedical Research Institute (IDIBELL) is a research centre created in 2004 and specialising in cancer, neuroscience, translational medicine and regenerative medicine. It has a team of more than 1,500 professionals who, from 73 research groups, publish more than 1,400 scientific articles a year. L’IDIBELL is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Health Institute, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.
IDIBELL is a member of the Campus d’Excelencia Internacional of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centres accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the HR Excellence in Research program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Centre of the AECC Scientific Foundation (FCAECC).